Cationic micelle delivery of a multi‐epitope vaccine candidate derived from tumor‐associated antigens, causing regression in established CT26 colorectal tumors in mice

Among all the cancers, colorectal cancer (CRC) has the third mortality rank in both genders. Cancer vaccines have shown promising results in boosting patients' immune systems to fight cancer. Using the IEDB database, we predicted mouse MHC‐I (H2‐Ld) binding epitopes from four tumor‐associated a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biomedical materials research. Part A 2024-05, Vol.112 (5), p.733-742
Main Authors: Sabzehei, Faezeh, Taromchi, Amir Hossein, Ramazani, Ali, Nedaei, Keivan, Feizi, Abdolamir, Arsang‐Jang, Shahram, Danafar, Hossein
Format: Article
Language:English
Subjects:
Adenomatous polyposis coli
Animal models
Animals
Antigen (tumor-associated)
Antigens
Antigens, Neoplasm
Cancer
cancer vaccine
Cancer Vaccines
cationic micelle
Cations
Cell proliferation
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - therapy
Epitopes
Female
Humans
Immune response
Immune system
Immunization
Immunotherapy
Lymphocyte Activation
Lymphocytes
Major histocompatibility complex
Male
Mice
Micelles
multi‐epitope antigen
Oleic acid
Polyethyleneimine
Tumors
tumor‐associated antigens
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Among all the cancers, colorectal cancer (CRC) has the third mortality rank in both genders. Cancer vaccines have shown promising results in boosting patients' immune systems to fight cancer. Using the IEDB database, we predicted mouse MHC‐I (H2‐Ld) binding epitopes from four tumor‐associated antigens (APC, KRAS, TP53, and PIK3CA) and designed a multi‐epitope vaccine. We expressed the candidate vaccine and encapsulated it into the cationic micelle with polyethyleneimine conjugated to oleic acid as its building blocks. We studied tumor inhibition effect, cytokine production, and lymphocyte proliferation in the mouse CRC model after vaccination. Our finding illustrated significant tumor growth inhibition in mouse models treated with the candidate nanovaccine. Besides the significant release of IFN‐γ and IL‐4 by immunized mouse spleen T‐lymphocytes, T‐cell proliferation assay results confirmed effective immune response after the vaccination. These results demonstrate the potential therapeutic effects of nanovaccines and could be a possible approach to CRC immunotherapy.
ISSN:1549-3296
1552-4965
DOI:10.1002/jbm.a.37654